NQO1 and schizophrenia: In an in vivo model of schizophrenia induced by the administration of phencyclidine (PCP), Andro reduced the levels of IL-1β and TNF-α, p-p65, p-IκBα, p-p38, and p-ERK1/2 in the prefrontal cortex; improved oxidative stress through the activation of antioxidant enzymes such as SOD, CAT, and GSH-Px; and increased the levels of NRF-2, HO-1, and NAD(P)H Quinone Dehydrogenase 1 (NQO-1).